Tags

Type your tag names separated by a space and hit enter

Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology.
Anticancer Res. 1996 Jul-Aug; 16(4B):2135-9.AR

Abstract

The past seven years has witnessed the development of research assays and now commercial assays for the measurement of a fragment of the beta subunit of human chorionic gonadotropin (beta-hCG). This fragment has been called the beta core fragment (beta-core), urinary gonadotropin fragment (UGF) and most recently urinary gonadotropin peptide (UGP). Clinical applications of UGP have been pursued most often but not exclusively in gynecologic oncology. This review presents evidence for a role for UGP in (1) the screening of women at high risk for ovarian cancer by virtue of their family history, (2) the differentiation of benign pelvic masses from malignant ones, particularly in premenopausal women and (3) monitoring women known to have previously been diagnosed with ovarian cancer and possibly cervical and advanced uterine cancer to determine efficacy of therapy.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Yale University School of Medicine, New Haven, Connecticut 06520, USA.No affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

8694533

Citation

Schwartz, P E., et al. "Clinical Applications of Urinary Gonadotropin Peptides (UGP) in Gynecologic Oncology." Anticancer Research, vol. 16, no. 4B, 1996, pp. 2135-9.
Schwartz PE, Cracchiolo BM, Cole LA. Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology. Anticancer Res. 1996;16(4B):2135-9.
Schwartz, P. E., Cracchiolo, B. M., & Cole, L. A. (1996). Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology. Anticancer Research, 16(4B), 2135-9.
Schwartz PE, Cracchiolo BM, Cole LA. Clinical Applications of Urinary Gonadotropin Peptides (UGP) in Gynecologic Oncology. Anticancer Res. 1996 Jul-Aug;16(4B):2135-9. PubMed PMID: 8694533.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Clinical applications of urinary gonadotropin peptides (UGP) in gynecologic oncology. AU - Schwartz,P E, AU - Cracchiolo,B M, AU - Cole,L A, PY - 1996/7/1/pubmed PY - 1996/7/1/medline PY - 1996/7/1/entrez SP - 2135 EP - 9 JF - Anticancer research JO - Anticancer Res VL - 16 IS - 4B N2 - The past seven years has witnessed the development of research assays and now commercial assays for the measurement of a fragment of the beta subunit of human chorionic gonadotropin (beta-hCG). This fragment has been called the beta core fragment (beta-core), urinary gonadotropin fragment (UGF) and most recently urinary gonadotropin peptide (UGP). Clinical applications of UGP have been pursued most often but not exclusively in gynecologic oncology. This review presents evidence for a role for UGP in (1) the screening of women at high risk for ovarian cancer by virtue of their family history, (2) the differentiation of benign pelvic masses from malignant ones, particularly in premenopausal women and (3) monitoring women known to have previously been diagnosed with ovarian cancer and possibly cervical and advanced uterine cancer to determine efficacy of therapy. SN - 0250-7005 UR - https://www.unboundmedicine.com/medline/citation/8694533/Clinical_applications_of_urinary_gonadotropin_peptides__UGP__in_gynecologic_oncology_ DB - PRIME DP - Unbound Medicine ER -